- Browse by Author
Browsing by Author "Holmans, Peter"
Now showing 1 - 3 of 3
Results Per Page
Sort Options
Item Genome-wide association identifies the first risk loci for psychosis in Alzheimer disease(Springer Nature, 2021) DeMichele-Sweet, Mary Ann A.; Klei, Lambertus; Creese, Byron; Harwood, Janet C.; Weamer, Elise A.; McClain, Lora; Sims, Rebecca; Hernandez, Isabel; Moreno-Grau, Sonia; Tárraga, Lluís; Boada, Mercè; Alarcón-Martín, Emilio; Valero, Sergi; NIA-LOAD Family Based Study Consortium; Alzheimer’s Disease Genetics Consortium (ADGC); Liu, Yushi; Hooli, Basavaraj; Aarsland, Dag; Selbaek, Geir; Bergh, Sverre; Rongve, Arvid; Saltvedt, Ingvild; Skjellegrind, Håvard K.; Engdahl, Bo; Stordal, Eystein; Andreassen, Ole A.; Djurovic, Srdjan; Athanasiu, Lavinia; Seripa, Davide; Borroni, Barbara; Albani, Diego; Forloni, Gianluigi; Mecocci, Patrizia; Serretti, Alessandro; De Ronchi, Diana; Politis, Antonis; Williams, Julie; Mayeux, Richard; Foroud, Tatiana; Ruiz, Agustín; Ballard, Clive; Holmans, Peter; Lopez, Oscar L.; Kamboh, M. Ilyas; Devlin, Bernie; Sweet, Robert A.; Medical and Molecular Genetics, School of MedicinePsychotic symptoms, defined as the occurrence of delusions or hallucinations, are frequent in Alzheimer disease (AD with psychosis, AD + P). AD + P affects ~50% of individuals with AD, identifies a subgroup with poor outcomes, and is associated with a greater degree of cognitive impairment and depressive symptoms, compared to subjects without psychosis (AD - P). Although the estimated heritability of AD + P is 61%, genetic sources of risk are unknown. We report a genome-wide meta-analysis of 12,317 AD subjects, 5445 AD + P. Results showed common genetic variation accounted for a significant portion of heritability. Two loci, one in ENPP6 (rs9994623, O.R. (95%CI) 1.16 (1.10, 1.22), p = 1.26 × 10-8) and one spanning the 3'-UTR of an alternatively spliced transcript of SUMF1 (rs201109606, O.R. 0.65 (0.56-0.76), p = 3.24 × 10-8), had genome-wide significant associations with AD + P. Gene-based analysis identified a significant association with APOE, due to the APOE risk haplotype ε4. AD + P demonstrated negative genetic correlations with cognitive and educational attainment and positive genetic correlation with depressive symptoms. We previously observed a negative genetic correlation with schizophrenia; instead, we now found a stronger negative correlation with the related phenotype of bipolar disorder. Analysis of polygenic risk scores supported this genetic correlation and documented a positive genetic correlation with risk variation for AD, beyond the effect of ε4. We also document a small set of SNPs likely to affect risk for AD + P and AD or schizophrenia. These findings provide the first unbiased identification of the association of psychosis in AD with common genetic variation and provide insights into its genetic architecture.Item Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia(Nature Publishing Group, 2014-09) Ruderfer, Douglas M.; Fanous, Ayman H.; Ripke, Stephan; McQuillin, Andrew; Amdur, Richard L.; Gejman, Pablo V.; O’Donovan, Michael C.; Andreassen, Ole A.; Djurovic, Srdjan; Hultman, Christina M.; Kelsoe, John R.; Jamain, Stephane; Landén, Mikael; Leboyer, Marion; Nimgaonkar, Vishwajit; Nurnberger, John; Smoller, Jordan W.; Craddock, Nick; Corvin, Aiden; Sullivan, Patrick F.; Holmans, Peter; Sklar, Pamela; Kendler, Kenneth S.; Department of Medical & Molecular Genetics, IU School of MedicineBipolar disorder and schizophrenia are two often severe disorders with high heritabilities. Recent studies have demonstrated a large overlap of genetic risk loci between these disorders but diagnostic and molecular distinctions still remain. Here, we perform a combined GWAS of 19,779 BP and SCZ cases versus 19,423 controls, in addition to a direct comparison GWAS of 7,129 SCZ cases versus 9,252 BP cases. In our case-control analysis, we identify five previously identified regions reaching genome-wide significance (CACNA1C, IFI44L, MHC, TRANK1, MAD1L1) and a novel locus near PIK3C2A. We create a polygenic risk score that is significantly different between BP and SCZ and show a significant correlation between a BP polygenic risk score and the clinical dimension of mania in SCZ patients. Our results indicate that first, combining diseases with similar genetic risk profiles improves power to detect shared risk loci and second, that future direct comparisons of BP and SCZ are likely to identify loci with significant differential effects. Identifying these loci should aid in the fundamental understanding of how these diseases differ biologically. These findings also indicate that combining clinical symptom dimensions and polygenic signatures could provide additional information that may someday be used clinically.Item A polygenic resilience score moderates the genetic risk for schizophrenia(Springer Nature, 2021-03) Hess, Jonathan L.; Tylee, Daniel S.; Mattheisen, Manuel; Børglum, Anders D.; Als, Thomas D.; Grove, Jakob; Werge, Thomas; Mortensen, Preben Bo; Mors, Ole; Nordentoft, Merete; Hougaard, David M.; Byberg-Grauholm, Jonas; Bækvad-Hansen, Marie; Greenwood, Tiffany A.; Tsuang, Ming T.; Curtis, David; Steinberg, Stacy; Sigurdsson, Engilbert; Stefánsson, Hreinn; Stefánsson, Kári; Edenberg, Howard J.; Holmans, Peter; Faraone, Stephen V.; Glatt, Stephen J.; Biochemistry and Molecular Biology, School of MedicineBased on the discovery by the Resilience Project (Chen R. et al. Nat Biotechnol 34:531–538, 2016) of rare variants that confer resistance to Mendelian disease, and protective alleles for some complex diseases, we posited the existence of genetic variants that promote resilience to highly heritable polygenic disorders1,0 such as schizophrenia. Resilience has been traditionally viewed as a psychological construct, although our use of the term resilience refers to a different construct that directly relates to the Resilience Project, namely: heritable variation that promotes resistance to disease by reducing the penetrance of risk loci, wherein resilience and risk loci operate orthogonal to one another. In this study, we established a procedure to identify unaffected individuals with relatively high polygenic risk for schizophrenia, and contrasted them with risk-matched schizophrenia cases to generate the first known “polygenic resilience score” that represents the additive contributions to SZ resistance by variants that are distinct from risk loci. The resilience score was derived from data compiled by the Psychiatric Genomics Consortium, and replicated in three independent samples. This work establishes a generalizable framework for finding resilience variants for any complex, heritable disorder.